Convenia

RSS

cefovecin

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 26/04/2018

Authorisation details

Product details
Name
Convenia
Agency product number
EMEA/V/C/000098
Active substance
cefovecin
International non-proprietary name (INN) or common name
cefovecin
Species
  • Dogs
  • Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
QJ01DD91
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Revision
10
Date of issue of marketing authorisation valid throughout the European Union
19/06/2006
Contact address
Rue Laid Burnait, 1
1348 Louvain-la-Neuve
Belgium

Product information

12/04/2018 Convenia - EMEA/V/C/000098 - IB/0032/G

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antibacterials for systemic use (cephalosporins)

Therapeutic indication

Dogs

For the treatment of skin and soft-tissue infections including pyoderma, wounds and abscesses associated with Staphylococcus pseudintermedius, β-haemolytic streptococci, Escherichia coli and / or Pasteurella multocida.

For the treatment of urinary-tract infections associated with Escherichia coli and / or Proteus spp.

As adjunctive treatment to mechanical or surgical periodontal therapy in the treatment of severe infections of the gingiva and periodontal tissues associated with Porphyromonas spp. and Prevotella spp.

Cats

For the treatment of skin and soft-tissue abscesses and wounds associated with Pasteurella multocida, Usobacterium spp., Bacteroides spp., Prevotella oralis, β-haemolytic streptococci and / or Staphylococcus pseudintermedius.

For the treatment of urinary-tract infections associated with Escherichia coli.

Assessment history

How useful was this page?

Add your rating